Skip to main content

Table 1 Baseline characteristics of patients

From: Accuracy of the clinical pulmonary infection score to differentiate ventilator-associated tracheobronchitis from ventilator-associated pneumonia

  Derivation cohort P value Validation cohort P value
VAT (n = 320) VAP (n = 369) VAT (n = 70) VAP (n = 136)
Sex
 Male 199 (62%) 264 (72%)   51 (73%) 102 (75%)  
 Female 121 (38%) 105 (28%) 0.009 19 (27%) 34 (25%) 0.74
Age (years) 61.20 (16.25) 57.74 (18.46) 0.009 55.26 (16.1) 54.98 (16.36) 0.89
SAPS II 48.85 (18.12) 49.89 (17.80) 0.45 54.6 (19.46) 59.97 (16.68) 0.079
SOFA 7.64 (3.79) 8.07 (3.63) 0.13 7.19 (4.34) 8.9 (4.04) 0.008
Admission category
 Medical 175 (55%) 218 (59%)   57 (81%) 117 (86%)  
 Surgical 145 (45%) 151 (41%) 0.25 13 (19%) 19 (14%) 0.39
 COPD 64 (20%) 61 (17%) 0.24 6 (10%) 21 (15%) 0.17
 Diabetes mellitus 66 (21%) 69 (19%) 0.53 14 (20%) 26 (20%) 0.88
 Immunocompromised patients 24 (8%) 31 (8%) 0.66 7 (10%) 23 (17%) 0.18
 Chronic heart failure 27 (8%) 19 (5%) 0.085 16 (23%) 16 (12%) 0.037
 Chronic respiratory failure 35 (11%) 27 (7%) 0.098 3 (4%) 7 (5%) 0.78
 Cirrhosis 8 (2%) 23 (6%) 0.018 3 (4%) 10 (7%) 0.38
 Previous antibiotic use 210 (66%) 232 (63%) 0.45 60 (86%) 107 (79%) 0.3
 Appropriate initial antimicrobial therapy 174 (54%) 257 (70%) < 0.001 40 (57%) 55 (40%) 0.023
  1. Data are presented as number (%) or mean (SD)
  2. COPD Chronic obstructive pulmonary disease, SAPS Simplified acute physiology score, SOFA Sequential organ failure assessment, VAP Ventilator-associated pneumonia, VAT Ventilator-associated tracheobronchitis
  3. p value < 0.05 is indicated in italic characters